SNDX
Price
$9.55
Change
-$0.12 (-1.24%)
Updated
Jul 18, 04:04 PM (EDT)
Capitalization
832.08M
24 days until earnings call
SVRA
Price
$2.26
Change
-$0.08 (-3.42%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
404.44M
20 days until earnings call
Interact to see
Advertisement

SNDX vs SVRA

Header iconSNDX vs SVRA Comparison
Open Charts SNDX vs SVRABanner chart's image
Syndax Pharmaceuticals
Price$9.55
Change-$0.12 (-1.24%)
Volume$2K
Capitalization832.08M
Savara
Price$2.26
Change-$0.08 (-3.42%)
Volume$13.64K
Capitalization404.44M
SNDX vs SVRA Comparison Chart in %
Loading...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SNDX vs. SVRA commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SNDX is a Hold and SVRA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (SNDX: $9.67 vs. SVRA: $2.34)
Brand notoriety: SNDX and SVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SNDX: 66% vs. SVRA: 41%
Market capitalization -- SNDX: $832.08M vs. SVRA: $404.44M
SNDX [@Biotechnology] is valued at $832.08M. SVRA’s [@Biotechnology] market capitalization is $404.44M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SNDX’s FA Score shows that 1 FA rating(s) are green whileSVRA’s FA Score has 0 green FA rating(s).

  • SNDX’s FA Score: 1 green, 4 red.
  • SVRA’s FA Score: 0 green, 5 red.
According to our system of comparison, SNDX is a better buy in the long-term than SVRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SNDX’s TA Score shows that 4 TA indicator(s) are bullish while SVRA’s TA Score has 4 bullish TA indicator(s).

  • SNDX’s TA Score: 4 bullish, 4 bearish.
  • SVRA’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, SVRA is a better buy in the short-term than SNDX.

Price Growth

SNDX (@Biotechnology) experienced а -1.53% price change this week, while SVRA (@Biotechnology) price change was +1.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.49%. For the same industry, the average monthly price growth was +13.01%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

SNDX is expected to report earnings on Nov 11, 2025.

SVRA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNDX($832M) has a higher market cap than SVRA($404M). SVRA YTD gains are higher at: -23.779 vs. SNDX (-26.853). SVRA has higher annual earnings (EBITDA): -108.24M vs. SNDX (-318.27M). SNDX has more cash in the bank: 516M vs. SVRA (172M). SNDX has less debt than SVRA: SNDX (1.84M) vs SVRA (29.6M). SNDX has higher revenues than SVRA: SNDX (43.7M) vs SVRA (0).
SNDXSVRASNDX / SVRA
Capitalization832M404M206%
EBITDA-318.27M-108.24M294%
Gain YTD-26.853-23.779113%
P/E RatioN/AN/A-
Revenue43.7M0-
Total Cash516M172M300%
Total Debt1.84M29.6M6%
FUNDAMENTALS RATINGS
SNDX vs SVRA: Fundamental Ratings
SNDX
SVRA
OUTLOOK RATING
1..100
1218
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
8964
P/E GROWTH RATING
1..100
3100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SVRA's Valuation (68) in the Biotechnology industry is in the same range as SNDX (84). This means that SVRA’s stock grew similarly to SNDX’s over the last 12 months.

SVRA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SNDX (100). This means that SVRA’s stock grew similarly to SNDX’s over the last 12 months.

SVRA's SMR Rating (98) in the Biotechnology industry is in the same range as SNDX (98). This means that SVRA’s stock grew similarly to SNDX’s over the last 12 months.

SVRA's Price Growth Rating (64) in the Biotechnology industry is in the same range as SNDX (89). This means that SVRA’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for SVRA (100). This means that SNDX’s stock grew significantly faster than SVRA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SNDXSVRA
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
71%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
72%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 26 days ago
77%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
87%
Aroon
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SNYNF98.082.19
+2.28%
Sanofi
LTMCF0.440.01
+1.60%
Lithium Chile Inc.
CRGGF2.81N/A
N/A
China Resources Gas Group Ltd
DSKIF24.83N/A
N/A
Daiseki Co., Ltd.
RDUFF0.12-0.01
-4.00%
Radius Gold Inc.